CL2009000422A1 - Formulacion topica que incluye un compuesto derivado de piperazina y uno o mas potenciadores de penetracion, util para tratar un trastorno en la piel mediado por estearoil-coa desaturasa tal como acne, rosacea y dermatitis seborreica. - Google Patents

Formulacion topica que incluye un compuesto derivado de piperazina y uno o mas potenciadores de penetracion, util para tratar un trastorno en la piel mediado por estearoil-coa desaturasa tal como acne, rosacea y dermatitis seborreica.

Info

Publication number
CL2009000422A1
CL2009000422A1 CL2009000422A CL2009000422A CL2009000422A1 CL 2009000422 A1 CL2009000422 A1 CL 2009000422A1 CL 2009000422 A CL2009000422 A CL 2009000422A CL 2009000422 A CL2009000422 A CL 2009000422A CL 2009000422 A1 CL2009000422 A1 CL 2009000422A1
Authority
CL
Chile
Prior art keywords
rosacea
stearoyl
acne
treating
useful
Prior art date
Application number
CL2009000422A
Other languages
English (en)
Inventor
Bilich Andreas
D Winther Michael
Paul Goldberg Yigal
Winzenburg Gesine
Rapp Karin
Fritze Andreas
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39970096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000422(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of CL2009000422A1 publication Critical patent/CL2009000422A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Formulación tópica que incluye un compuesto derivado de piridazina y uno o más potenciadores de penetración, útil para tratar un trastorno en la piel mediado por estearoil-coa de saturasa tal como acné, rosácea y dermatitis seborreica.
CL2009000422A 2008-02-25 2009-02-25 Formulacion topica que incluye un compuesto derivado de piperazina y uno o mas potenciadores de penetracion, util para tratar un trastorno en la piel mediado por estearoil-coa desaturasa tal como acne, rosacea y dermatitis seborreica. CL2009000422A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/036,685 US7759348B2 (en) 2003-07-30 2008-02-25 Pyridazine derivatives and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
CL2009000422A1 true CL2009000422A1 (es) 2010-09-21

Family

ID=39970096

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000422A CL2009000422A1 (es) 2008-02-25 2009-02-25 Formulacion topica que incluye un compuesto derivado de piperazina y uno o mas potenciadores de penetracion, util para tratar un trastorno en la piel mediado por estearoil-coa desaturasa tal como acne, rosacea y dermatitis seborreica.

Country Status (15)

Country Link
US (3) US7759348B2 (es)
EP (1) EP2257291A2 (es)
JP (1) JP2011513296A (es)
KR (1) KR20100126434A (es)
CN (1) CN101980709A (es)
AR (1) AR070852A1 (es)
AU (1) AU2009219809A1 (es)
BR (1) BRPI0908225A2 (es)
CA (1) CA2716336A1 (es)
CL (1) CL2009000422A1 (es)
MX (1) MX2010009206A (es)
PE (1) PE20091557A1 (es)
RU (1) RU2010139285A (es)
TW (1) TW200940060A (es)
WO (1) WO2009106991A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1887875B (zh) * 2005-06-30 2011-04-06 深圳市东阳光实业发展有限公司 哒嗪胺衍生物及其用于制备小rna病毒抑制剂的用途
DK2142529T3 (da) * 2007-04-27 2014-02-10 Purdue Pharma Lp Trpv1-antagonister og anvendelser deraf
EP2236505A1 (de) * 2009-04-03 2010-10-06 Bayer CropScience AG Acylierte Aminopyridine und - pyridazine als Insektizide
FR2948939B1 (fr) 2009-08-05 2013-03-22 Pf Medicament Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine
FR2950807B1 (fr) * 2009-10-06 2012-02-03 Lvmh Rech Composition cosmetique contenant des liposomes encapsules dans un compose oxazolidin-2-one
FR2958935B1 (fr) 2010-04-19 2012-06-22 Pf Medicament Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine
EP2659001A4 (en) * 2010-12-31 2014-07-02 Zeus Scientific Inc IMPROVED METHODS FOR DETERMINING THE VITABILITY OF CELLS USING NUCLEIC ACID-BASED PROCESSES
HRP20170507T1 (hr) 2011-06-22 2017-06-02 Purdue Pharma Lp Trpv1 antagonisti uključujući dihidroksi supstituente i njihove uporabe
WO2013134546A1 (en) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US20160175324A1 (en) * 2013-08-08 2016-06-23 Galderm Therapeutics Ltd. Anti-acne compositions comprising bile acid-fatty acid conjugates
US10301318B2 (en) * 2014-06-25 2019-05-28 The General Hospital Corporation Neuroactive compounds and methods of using the same
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
US10703712B2 (en) 2015-09-16 2020-07-07 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
JP6583126B2 (ja) * 2016-04-28 2019-10-02 信越化学工業株式会社 新規カルボン酸オニウム塩、化学増幅レジスト組成物、及びパターン形成方法
AU2017281907B2 (en) 2016-06-23 2021-10-21 St. Jude Children's Research Hospital, Inc. Small molecule modulators of pantothenate kinases
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3055990A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP7258763B2 (ja) 2017-03-15 2023-04-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
US11018285B2 (en) 2017-03-23 2021-05-25 Seoul Semiconductor Co., Ltd. Display device and manufacturing method thereof
US10821075B1 (en) * 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
EP3731859B1 (en) 2017-12-27 2025-08-20 St. Jude Children's Research Hospital, Inc. Pyridazine compounds for use to treat disorders associated with castor
KR102728619B1 (ko) * 2017-12-27 2024-11-08 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 판토테네이트 키나제의 소분자 조절제
JP7291711B2 (ja) * 2018-02-15 2023-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｒｐｃ６阻害剤
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
AU2019344903B2 (en) 2018-09-18 2025-02-27 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
CA3135011A1 (en) 2019-03-27 2020-10-01 St. Jude Children's Research Hospital Small molecule modulators of pank
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
WO2021188695A1 (en) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist
KR20220155356A (ko) 2020-03-18 2022-11-22 메타크린, 인크. 파르네소이드 x 수용체 효능제의 결정형
EP4555995A1 (fr) * 2023-11-14 2025-05-21 Laboratoires d'Anjou Utilisation d'un acide gras cyclopropénique pour inhiber l'activité de la scd

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
AU8096798A (en) 1997-06-27 1999-01-19 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
JP2003533965A (ja) * 1998-08-14 2003-11-18 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 皮膚の異常症状を治療するためのヒト・ステアロイル−ＣｏＡデサチュラーゼ−関連組成物および方法
AU5774699A (en) 1998-08-14 2000-03-06 Johnson & Johnson Consumer Companies, Inc. Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
JP3637961B2 (ja) 1999-09-16 2005-04-13 田辺製薬株式会社 芳香族含窒素六員環化合物
EP1315831B8 (en) 2000-02-24 2010-09-01 Xenon Pharmaceuticals Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
US7160878B2 (en) 2000-07-27 2007-01-09 Eli Lilly And Company Substituted heterocyclic amides
IL158941A0 (en) 2001-05-22 2004-05-12 Neurogen Corp Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
KR20040010713A (ko) 2001-06-15 2004-01-31 야마노우치세이야쿠 가부시키가이샤 페닐피리딘 카보닐 피페라진 유도체
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7330129B2 (en) * 2003-07-16 2008-02-12 Black & Decker Inc. System and method for data retrieval in AC power tools via an AC line cord
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP1648874B1 (en) * 2003-07-30 2011-10-05 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
CN101712653A (zh) * 2003-07-30 2010-05-26 泽农医药公司 哒嗪衍生物和它们作为治疗剂的用途
CN1829701A (zh) * 2003-07-30 2006-09-06 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途
EP1807085B1 (en) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2008003753A1 (en) * 2006-07-07 2008-01-10 Biovitrum Ab (Publ) Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity

Also Published As

Publication number Publication date
WO2009106991A2 (en) 2009-09-03
US7759348B2 (en) 2010-07-20
US20110021530A1 (en) 2011-01-27
AR070852A1 (es) 2010-05-12
BRPI0908225A2 (pt) 2016-11-01
RU2010139285A (ru) 2012-04-10
CN101980709A (zh) 2011-02-23
AU2009219809A1 (en) 2009-09-03
EP2257291A2 (en) 2010-12-08
US7964591B2 (en) 2011-06-21
PE20091557A1 (es) 2009-10-30
CA2716336A1 (en) 2009-09-03
KR20100126434A (ko) 2010-12-01
US20080280916A1 (en) 2008-11-13
US20100311763A1 (en) 2010-12-09
JP2011513296A (ja) 2011-04-28
MX2010009206A (es) 2010-11-10
TW200940060A (en) 2009-10-01
WO2009106991A3 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
CL2009000422A1 (es) Formulacion topica que incluye un compuesto derivado de piperazina y uno o mas potenciadores de penetracion, util para tratar un trastorno en la piel mediado por estearoil-coa desaturasa tal como acne, rosacea y dermatitis seborreica.
CR20140117A (es) Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus métodos y usos
DOP2016000164A (es) Mezclas fungicidas sinérgicas para el control fúngico en cereales
UY34788A (es) ?picolinamidas macrocíclicas como fungicidas, composición y método para control y prevención del ataque fúngico en plantas?.
CL2011002648A1 (es) Composicion topica que comprende un compuesto derivado de 1,2,4-tiadiazol o tiourea, un agente modificador de la viscosidad, un conservante y agua; estuche para la composicion; metodo para preparar la composicion; y uso para tratar una enfermedad o trastorno dermatologico mediado por un receptor de melanocortina tal como acne.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
PH12014501786A1 (en) Compounds for treating spinal muscular atrophy
MX357834B (es) Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
MX2014010406A (es) Compuestos para tratar atrofia muscular espinal.
CR20110043A (es) Mezclas fungicidas que comprenden 1-metilpirazol-4-ilcarboxanilidas sustituidas
PH12013501524A1 (en) Topical minocycline compositions and methods of using the same
CL2014001848A1 (es) Composicion herbicida que contiene bentazon-sodico, un inhibidor de als y un inhibidor de accasa; y metodo para controlar vegetacion no deseada.
MX2015017927A (es) Cojinete para uso en cabecera deslizante.
UY34280A (es) Nuevos compuestos que tienen actividad inhibidora frente a la daminoacido oxidasa.
PE20121709A1 (es) Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica
UY33944A (es) Oxo y sulfono heterociclos herbicidas que contienen bis-hidrógeno
CL2012002506A1 (es) Compuestos derivados de heterociclos sustituidos, inhibidores de la enzima pde10; composiciones farmacéuticas que comprenden dichos compuestos; y un método para tratar desórdenes neurológicos en un animal de sangre caliente, tal como esquizofrenia.
CL2011000128A1 (es) Procedimiento para la extraccion de componentes de uranio con acido fosforico en via humeda (wpa) que comprende la reduccion del contenido de hierro del wpa, reduccion de la valencia de cualquier remanente de hierro en el wpa y extraccion de los componentes de uranio del wpa.
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
BR112015014885A2 (pt) combinação de agentes ativos, composição cosmética e/ou dermatológica e processo para a preparação de uma composição de agentes ativos.
BR112012023942A2 (pt) curativo para feridas e processo para a preparação de um curativo para feridas.
CL2009001363S1 (es) Pieza para maquina de afeitar.
BR112013004192A2 (pt) tratamento de hipertensão e/ou prevenção ou tratamento de falha do coração em um mamífero que recebe terapia de anticoagulante
ECSP11011166A (es) Agente preventivo/terapéutico contra el cáncer
UA107684C2 (xx) АГОНІСТИ РЕЦЕПТОРА mGlu2